Filing Flows › Mirum Pharmaceuticals (MIRM) › How it makes money
How Mirum Pharmaceuticals (MIRM) makes money
Mirum Pharmaceuticals (MIRM) made $186M of revenue in the third quarter 2026 (Q3 2026), +40% from a year earlier. Livmarli brought in $133M (72%); Bile Acid Medicines brought in $52.3M (28%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Livmarli | $133M | 71.9% | +4% | +45% |
| Bile Acid Medicines | $52.3M | 28.1% | +10% | +28% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $186M | 100.0% |
| Income tax | $538K | 0.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $186M | +40% |
| Q2 2026 | $176M | +38% |
| Q1 2026 | $160M | +43% |
| Q4 2025 | $149M | +50% |
| Q3 2025 | $133M | +47% |
| Q2 2025 | $128M | +64% |
| Q1 2025 | $112M | +61% |
From Mirum Pharmaceuticals' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Mirum Pharmaceuticals make money?
Mirum Pharmaceuticals (MIRM) made $186M of revenue in the third quarter 2026 (Q3 2026), +40% from a year earlier. Livmarli brought in $133M (72%); Bile Acid Medicines brought in $52.3M (28%).
What is Mirum Pharmaceuticals' biggest business?
Livmarli: $133M in the third quarter 2026, 72% of revenue, +45% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.